1Osanai T, Saitoh M, Sasaki S, et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells[J]. Hypertension, 2003,42 (5) : 985-990.
2Boger RH, Lentz SR, Bode-Boger SM, et al. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimentalhyperhomocyst (e) inaemia in humans[J]. Clin Sci(Lond) ,2001,100(2) : 161-167.
3Boger RH, Bode-Boger SM, Tsao PS, et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes[J]. J Am Coll Cardiol, 2000, 36 (7) :2287-2295.
4Xiao HB, Yang ZC, Jia SJ, et al. Effect of asymmetric dimethylarginine on atherogenesis and erythrocyte deformability in apolipoprotein E deficient mice[J]. Life Sci, 2007,81(1) :1-7.
5Toth J, Racz A, Kaminski PM, et al. Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone[J]. Hypertension,2007,49(3):563-568.
6Kielstein JT,Impraim B,Simmel S,et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans [J ]. Circulation, 2004, 109 ( 25 ) : e327.
8Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study[J]. Am Heart J, 2006,152 (3):493. e1-8.
9Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA[J]. Atheroscler Suppl,2003,4(4):61-65.
10Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine[J]. Lancet,2001,358(9299):2127-2128.
6Segarra G,Medina P,Ballester RM,et al. Effects of some guanidino compounds on human cerebral arteries[J]. Stroke, 1999,30 (10): 2206-2210.
7Takiuchi S,Fujii H,Kamide K ,et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients[J]. Am J Hypertens, 2004,17 (9) : 802-808.
8Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s[J]. Nature,1993,362(6423) :801-809.
9Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor[J].Cardiovasc Res, 2003, 59(4) : 824-833.
10Kinlay S, Selwyn AP, Delagrange D, el al. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points[J]. Curr Opin Lipidol,1996,7(6):389-397.
